H. Lundbeck A/S 0ND5.IL Stock
H. Lundbeck A/S Price Chart
H. Lundbeck A/S 0ND5.IL Financial and Trading Overview
| H. Lundbeck A/S stock price | 34.32 DKK |
| Previous Close | 36.75 DKK |
| Open | 36.7 DKK |
| Bid | 0 DKK x 0 |
| Ask | 0 DKK x 0 |
| Day's Range | 36.52 - 36.82 DKK |
| 52 Week Range | 23.36 - 39.84 DKK |
| Volume | 4.82K DKK |
| Avg. Volume | 236.35K DKK |
| Market Cap | 35.89B DKK |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 15.153526 |
| EPS (TTM) | 2.46 DKK |
| Forward Dividend & Yield | 0.58 (1.61%) |
| Ex-Dividend Date | March 22, 2023 |
| 1y Target Est | N/A |
0ND5.IL Valuation Measures
| Enterprise Value | 38.33B DKK |
| Trailing P/E | 15.153526 |
| Forward P/E | 16.6 |
| PEG Ratio (5 yr expected) | 40.97 |
| Price/Sales (ttm) | 1.8971733 |
| Price/Book (mrq) | 1.7285119 |
| Enterprise Value/Revenue | 2.026 |
| Enterprise Value/EBITDA | 7.845 |
Trading Information
H. Lundbeck A/S Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 9.36% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 39.84 DKK |
| 52 Week Low | 23.36 DKK |
| 50-Day Moving Average | 35.65 DKK |
| 200-Day Moving Average | 29.56 DKK |
0ND5.IL Share Statistics
| Avg. Volume (3 month) | 236.35K DKK |
| Avg. Daily Volume (10-Days) | 158.29K DKK |
| Shares Outstanding | 794.27M |
| Float | 307.04M |
| Short Ratio | N/A |
| % Held by Insiders | 0.074% |
| % Held by Institutions | 75.49% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.58 |
| Trailing Annual Dividend Yield | 1.57% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.24069999 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 12.60% |
| Operating Margin (ttm) | 16.23% |
| Gross Margin | 78.07% |
| EBITDA Margin | 25.82% |
Management Effectiveness
| Return on Assets (ttm) | 5.35% |
| Return on Equity (ttm) | 12.09% |
Income Statement
| Revenue (ttm) | 18.92B DKK |
| Revenue Per Share (ttm) | 19.06 DKK |
| Quarterly Revenue Growth (yoy) | 15.40% |
| Gross Profit (ttm) | 14.3B DKK |
| EBITDA | 4.89B DKK |
| Net Income Avi to Common (ttm) | 2.38B DKK |
| Diluted EPS (ttm) | 2.41 |
| Quarterly Earnings Growth (yoy) | 113.59% |
Balance Sheet
| Total Cash (mrq) | 2.88B DKK |
| Total Cash Per Share (mrq) | 2.9 DKK |
| Total Debt (mrq) | 5.22B DKK |
| Total Debt/Equity (mrq) | 24.9 DKK |
| Current Ratio (mrq) | 1.495 |
| Book Value Per Share (mrq) | 21.128 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 4.1B DKK |
| Levered Free Cash Flow (ttm) | 1.77B DKK |
Profile of H. Lundbeck A/S
| Country | United Kingdom |
| State | N/A |
| City | Valby |
| Address | Ottiliavej 9 |
| ZIP | 2500 |
| Phone | 45 36 30 13 11 |
| Website | https://www.lundbeck.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 5500 |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Q&A For H. Lundbeck A/S Stock
What is a current 0ND5.IL stock price?
H. Lundbeck A/S 0ND5.IL stock price today per share is 34.32 DKK.
How to purchase H. Lundbeck A/S stock?
You can buy 0ND5.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for H. Lundbeck A/S?
The stock symbol or ticker of H. Lundbeck A/S is 0ND5.IL.
Which industry does the H. Lundbeck A/S company belong to?
The H. Lundbeck A/S industry is Drug Manufacturers-Specialty & Generic.
How many shares does H. Lundbeck A/S have in circulation?
The max supply of H. Lundbeck A/S shares is 1B.
What is H. Lundbeck A/S Price to Earnings Ratio (PE Ratio)?
H. Lundbeck A/S PE Ratio is 13.95082900 now.
What was H. Lundbeck A/S earnings per share over the trailing 12 months (TTM)?
H. Lundbeck A/S EPS is 2.46 DKK over the trailing 12 months.
Which sector does the H. Lundbeck A/S company belong to?
The H. Lundbeck A/S sector is Healthcare.